TheraRadar
← Back
Data updated: Jun 28, 2026

ARS PHARMS OPERATION

Pharma
Pharmaceuticals Execution: Good

ARS PHARMS OPERATION is a pharmaceutical company with 1 FDA-approved products.

2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

ARS PHARMS OPERATION at a Glance

  • Fast trial execution (18 months median completion)

ARS PHARMS OPERATION's Key Drugs

ARS PHARMS OPERATION's core commercial portfolio centers on NEFFY — its most strategically important drugs approved in the last 15 years.

NEFFY
Immunology

Anaphylaxis

alpha-adrenergic receptor Approved 2024

ARS PHARMS OPERATION's Recent FDA Approvals

ARS PHARMS OPERATION secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

NEFFY NDA
2024-08-09
epinephrine
Anaphylaxis

ARS PHARMS OPERATION's Therapeutic Areas

Disease areas where ARS PHARMS OPERATION has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

ARS PHARMS OPERATION Pipeline Snapshot

Active clinical trials for ARS PHARMS OPERATION across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NEFFY leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 18 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges